Lagatar24 Desk
New Delhi, June 17: Bharat Biotech stated on Friday that its anti-Covid vaccine BBV152 or Covaxin has been peer-reviewed and the study published in a top medical journal, indicating that it is safe and has low side effects in children aged 2 to 18.
According to the company’s release, trials for these 526 youngsters were undertaken at six hospitals in India last year to collect data. On June 16th, it was published online in The Lancet Infectious Diseases journal.
According to the manufacturer, 374 “adverse occurrences” or side effects were reported, the majority of which were moderate and resolved within a day. The most prevalent side effect was pain at the injection site.
In terms of effectiveness, the conclusion of a study published in the Lancet journal states that only the immunological response, not clinical efficacy, has been investigated in children.
In India, the vaccine has been approved for emergency use in children aged 6 to 18 years old – first for children aged 12 to 18 in December 2021, and then for children aged 6 to 12 in April of this year. In October 2021, trial data was submitted to the Central Drugs Standard Control Organization (CDSCO).
